Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up.

The article discusses a study on the formation of antidrug antibodies against fully human monoclonal antibody adalimumab and the clinical relevance of these antidrug antibodies during long-term follow-up of patients with rheumatoid arthritis (RA). The study involved 272 patients with RA and they started receiving adalimumab in an outpatient clinic. The researchers monitored disease activity and collected trough serum samples at baseline. The discontinuation of treatment, minimal disease activity and clinical remission in patients with and without antiadalimumab antibodies were compared. The study found higher adalimumab concentrations in patients without antiadalimumab antibodies. The researchers conclude that antidrug antibody development was linked with lower adalimumab concentration.